In a 2018 study, Zhao et al. tested the use of a novel Cas enzyme, namely Cas13a in a CRISPR system to specifically knockdown the KRAS G12D in pancreatic cancer cells, for the first time [112]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.